Skip to main content
Top
Published in: BMC Infectious Diseases 1/2019

Open Access 01-12-2019 | Tuberculosis | Research article

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India

Authors: Akshay N. Gupte, Dileep Kadam, Shashikala Sangle, Bharat B. Rewari, Sonali Salvi, Amol Chavan, Smita Nimkar, Jonathan Golub, Nikhil Gupte, Amita Gupta, Ivan Marbaniang, Vidya Mave

Published in: BMC Infectious Diseases | Issue 1/2019

Login to get access

Abstract

Background

Programmatic data on the baseline risk of tuberculosis in people living with HIV (PLHIV) are needed to evaluate long-term effectiveness of the ongoing isoniazid preventive therapy (IPT) roll-out in India.

Methods

We estimated the incidence rate and risk factors of tuberculosis disease in adult PLHIV initiating first- and second-line anti-retroviral therapy (ART) prior to widespread IPT in a public ART center in Pune, India.

Results

4067 participants contributing 5205.7 person-years of follow-up on first-line ART and 871 participants contributing 1031.7 person-years of follow-up on second-line ART were included in the analysis. The incidence rate of tuberculosis was 4.39 cases (95%CI 3.86–5.00) per 100 person-years on first-line ART and 1.64 cases (95%CI 1.01–2.63) per 100 person-years on second-line ART (p < 0.001). After adjusting for competing risks, male sex (aSHR = 1.33, 95%CI 1.02–1.74, p = 0.03), urban residence (aSHR = 1.53, 95%CI 1.13–2.07, p = 0.006) and CD4+ counts < 350 cells/mm3 (aSHR = 3.06 vs CD4 > 350 cells/mm3, 95%CI 1.58–5.94, p < 0.001) at ART initiation were associated with higher risk of tuberculosis independent of ART regimen.

Conclusion

Risk of tuberculosis was lower in PLHIV receiving second-line ART compared to first-line ART. Prioritizing IPT in PLHIV with low CD4+ counts, urban residence and in males may further mitigate the risk of tuberculosis during ART.
Appendix
Available only for authorised users
Literature
1.
go back to reference Global tuberculosis report. Geneva: World Health Organization;2018. Global tuberculosis report. Geneva: World Health Organization;2018.
2.
go back to reference Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One. 2013;8(5):e64915.CrossRef Gao J, Zheng P, Fu H. Prevalence of TB/HIV co-infection in countries except China: a systematic review and meta-analysis. PLoS One. 2013;8(5):e64915.CrossRef
3.
go back to reference Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290.CrossRef Campbell TB, Smeaton LM, Kumarasamy N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9(8):e1001290.CrossRef
4.
go back to reference Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization;2011. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization;2011.
5.
go back to reference India TB Report. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare;2018. India TB Report. New Delhi: Central TB Division, Directorate General of Health Services, Ministry of Health and Family Welfare;2018.
6.
go back to reference Guidelines on Prevention and Management of TB in PLHIV at ART Centers. New Delhi: National AIDS Control Organization, Ministry of Health and Family Welfare;2016. Guidelines on Prevention and Management of TB in PLHIV at ART Centers. New Delhi: National AIDS Control Organization, Ministry of Health and Family Welfare;2016.
7.
go back to reference Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Inculuding Post-exposure Prophylaxis. National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India;2007. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Inculuding Post-exposure Prophylaxis. National AIDS Control Organisation, Ministry of Health and Family Welfare, Government of India;2007.
8.
go back to reference Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRef Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRef
9.
go back to reference Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.CrossRef Suthar AB, Lawn SD, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270.CrossRef
10.
go back to reference Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15:517.CrossRef Chakravarty J, Sundar S, Chourasia A, et al. Outcome of patients on second line antiretroviral therapy under programmatic condition in India. BMC Infect Dis. 2015;15:517.CrossRef
11.
go back to reference Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2012;26(1):57–65.CrossRef Gsponer T, Petersen M, Egger M, et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2012;26(1):57–65.CrossRef
12.
go back to reference Thao VP, Quang VM, Wolbers M, et al. Second-line HIV therapy outcomes and determinants of mortality at the largest HIV referral Center in Southern Vietnam. Medicine (Baltimore). 2015;94(43):e1715.CrossRef Thao VP, Quang VM, Wolbers M, et al. Second-line HIV therapy outcomes and determinants of mortality at the largest HIV referral Center in Southern Vietnam. Medicine (Baltimore). 2015;94(43):e1715.CrossRef
13.
go back to reference Ramadhani HO, Bartlett JA, Thielman NM, et al. The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania. Open Forum Infect Dis. 2016;3(1):ofw018.CrossRef Ramadhani HO, Bartlett JA, Thielman NM, et al. The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania. Open Forum Infect Dis. 2016;3(1):ofw018.CrossRef
14.
go back to reference Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One. 2010;5(5):e10527.CrossRef Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One. 2010;5(5):e10527.CrossRef
15.
go back to reference Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a south African cohort. AIDS. 2005;19(18):2109–16.CrossRef Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a south African cohort. AIDS. 2005;19(18):2109–16.CrossRef
16.
go back to reference Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS. 2015;29(11):1391–9.CrossRef Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS. 2015;29(11):1391–9.CrossRef
17.
go back to reference Hira SK, Shroff HJ, Lanjewar DN, Dholkia YN, Bhatia VP, Dupont HL. The natural history of human immunodeficiency virus infection among adults in Mumbai. Natl Med J India. 2003;16(3):126–31.PubMed Hira SK, Shroff HJ, Lanjewar DN, Dholkia YN, Bhatia VP, Dupont HL. The natural history of human immunodeficiency virus infection among adults in Mumbai. Natl Med J India. 2003;16(3):126–31.PubMed
18.
go back to reference Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014;17:19251.CrossRef Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc. 2014;17:19251.CrossRef
19.
go back to reference Ghate M, Deshpande S, Tripathy S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13(1):e1–8.CrossRef Ghate M, Deshpande S, Tripathy S, et al. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts. Int J Infect Dis. 2009;13(1):e1–8.CrossRef
20.
go back to reference Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23(13):1717–25.CrossRef Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS. 2009;23(13):1717–25.CrossRef
21.
go back to reference Bock P, Jennings K, Vermaak R, et al. Incidence of tuberculosis among HIV-positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa. J Acquir Immune Defic Syndr. 2018;77(1):93–101.CrossRef Bock P, Jennings K, Vermaak R, et al. Incidence of tuberculosis among HIV-positive individuals initiating antiretroviral treatment at higher CD4 counts in the HPTN 071 (PopART) trial in South Africa. J Acquir Immune Defic Syndr. 2018;77(1):93–101.CrossRef
22.
go back to reference Group TAS, Danel C, Moh R, et al. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef Group TAS, Danel C, Moh R, et al. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.CrossRef
23.
go back to reference Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef Group ISS, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.CrossRef
24.
go back to reference Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016;387(10024):1198–209.CrossRef Hosseinipour MC, Bisson GP, Miyahara S, et al. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet. 2016;387(10024):1198–209.CrossRef
25.
go back to reference Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014;209(Suppl 3):S100–6.CrossRef Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014;209(Suppl 3):S100–6.CrossRef
26.
go back to reference Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123–32.PubMed Borgdorff MW, Nagelkerke NJ, Dye C, Nunn P. Gender and tuberculosis: a comparison of prevalence surveys with notification data to explore sex differences in case detection. Int J Tuberc Lung Dis. 2000;4(2):123–32.PubMed
Metadata
Title
Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India
Authors
Akshay N. Gupte
Dileep Kadam
Shashikala Sangle
Bharat B. Rewari
Sonali Salvi
Amol Chavan
Smita Nimkar
Jonathan Golub
Nikhil Gupte
Amita Gupta
Ivan Marbaniang
Vidya Mave
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2019
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-019-4569-z

Other articles of this Issue 1/2019

BMC Infectious Diseases 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.